Crossref
SA23 DIVERSITY IN CLINICAL TRIALS: A REVIEW OF DRUGS APPROVED BY THE FDA IN 2024
Value in Health · 2026-06 · 29 (6) · S443
DOI: 10.1016/j.jval.2026.03.2191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Sophia Cassim und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Cassim, S., Wright, A., & Agboola, F. O. (2026). SA23 DIVERSITY IN CLINICAL TRIALS: A REVIEW OF DRUGS APPROVED BY THE FDA IN 2024. Value in Health, 29(6), S443. https://doi.org/10.1016/j.jval.2026.03.2191
Vancouver
Cassim S, Wright A, Agboola FO. SA23 DIVERSITY IN CLINICAL TRIALS: A REVIEW OF DRUGS APPROVED BY THE FDA IN 2024. Value in Health. 2026;29(6):S443. doi:10.1016/j.jval.2026.03.2191
BibTeX
@article{Cassim2026,
author = {Cassim, Sophia and Wright, Abigail and Agboola, Foluso O.},
title = {SA23 DIVERSITY IN CLINICAL TRIALS: A REVIEW OF DRUGS APPROVED BY THE FDA IN 2024},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S443},
doi = {10.1016/j.jval.2026.03.2191}
}
EUVIMED